Quantum Genomics Société Anonyme Valuation

Is QNNT.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of QNNT.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate QNNT.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate QNNT.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for QNNT.F?

Key metric: As QNNT.F barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for QNNT.F. This is calculated by dividing QNNT.F's market cap by their current book value.
What is QNNT.F's PB Ratio?
PB Ratio	15.7x
Book	€436.66k
Market Cap	€6.85m

QNNT.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	304.2x
Enterprise Value/EBITDA	-2.1x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does QNNT.F's PB Ratio compare to its peers?

The above table shows the PB ratio for QNNT.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.6x
IMNN Imunon	1.4x	-22.0%	US$10.0m
BNOX Bionomics	0.3x	n/a	US$4.8m
BCDA BioCardia	2.9x	-13.5%	US$7.5m
ONVO Organovo Holdings	1.7x	-10.7%	US$5.4m
QNNT.F Quantum Genomics Société Anonyme	15.7x	n/a	US$6.9m

Price-To-Book vs Peers: QNNT.F is expensive based on its Price-To-Book Ratio (15.7x) compared to the peer average (2.8x).

Price to Book Ratio vs Industry

How does QNNT.F's PB Ratio compare vs other companies in the US Biotechs Industry?

60 Companies	Price / Book	Estimated Growth	Market Cap
GRAL GRAIL	0.2x	35.7%	US$550.38m
IMAB I-Mab	0.4x	1.8%	US$78.16m
ACET Adicet Bio	0.4x	6.7%	US$75.31m
MGX Metagenomi	0.3x	-23.2%	US$68.11m

60 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: QNNT.F is expensive based on its Price-To-Book Ratio (15.7x) compared to the US Biotechs industry average (2x).

Price to Book Ratio vs Fair Ratio

What is QNNT.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

QNNT.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	15.7x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate QNNT.F's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Kiniksa Pharmaceuticals International

US$1.5b

A biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.

KNSA

US$21.28

-0.05%

33.2%

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$17.12

4.2%

79.3%